정규장
Log in Sign up
LABT
LABT
Lakewood-Amedex Biotherapeutics Inc
7월 28일 12:54 PM ET (한국 7/29 01:54)
$2.48
-0.16 ▼ -6.06%

레이크우드-아메덱스 바이오테라퓨틱스(LABT) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$4M
스몰캡
P/E
-
배당수익률
없음
52주 위치
1%
저점 +49% · 고점 -97%
애널리스트
-
F
Fundamental health
vs. 미분류 초소형주· based on 1 axes
수익성
산출 불가 (적자)
성장
데이터 부족
밸류에이션
데이터 부족
재무 안정
Top 92%
Index -P/E -EPS (ttm) -8.8Insider Own 45.37%Shs Outstand 1.8MPerf Week 28.5%
Market Cap 0.00BForward P/E -EPS next Y -Insider Trans -Shs Float 1.0MPerf Month -27.7%
Enterprise Value 0.01BPEG -EPS next Q -0.65Inst Own -Short Float 2.5%Perf Quarter -96.63%
Income -0.00BP/S -EPS this Y -Inst Trans -Short Ratio 0.02Perf Half Y -
Sales 0.00BP/B -EPS next 5Y -ROA -834.41%Short Interest 0.02MPerf YTD -96.9%
Book/sh -4.04P/C 434EPS past 3/5Y 17.02% -ROE -52W High -97.47% ($98.20)Perf Year -
Cash/sh 0.01P/FCF -Sales past 3/5Y -ROIC -52W Low 49.4% ($1.66)Perf 3Y -
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -100%Gross Margin -Volatility(W/M) 38.16% 24.25%Perf 5Y -
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 1.13Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.02EPS Q/Q -1900%Profit Margin -RSI (14) 29.66Recom -
Dividend Gr. 3/5Y -Current Ratio 0.02Sales Q/Q -SMA20 -5.09% ($2.61)Beta -Target Price $12
Payout -Debt/Eq -Earnings 2026/06/03SMA50 -53.56% ($5.34)Rel Volume 0.19Prev Close $2.64
Employees 5LT Debt/Eq -EPS/Sales Surpr. -SMA200 -81.07% ($13.1)Avg Volume(3M) 1.60MPrice $2.48
IPO 2026/4/23Option/Short No/YesTrades 1902Volume 296,819Change -6.06%

📊 Lakewood-Amedex Biotherapeutics Inc (LABT) Investment Analysis

What kind of company is Lakewood-Amedex Biotherapeutics Inc?

레이크우드-아메덱스 바이오테라퓨틱스(LABT)
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

An early clinical-stage biotech company developing topical antibacterial drugs to treat antibiotic-resistant infections. Founded in 2015 and headquartered in Manatee County, Florida, the company began trading on the Nasdaq Capital Market in April 2026.

Learn more about Lakewood-Amedex Biotherapeutics Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5701
Employees5people
IPO2026/04/23
Current Price$2.48 ≈ 3,398원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 6월 3일 (수) · 장 마감 후

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
ROA
Annual earnings relative to total company assets
-834.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.02
✓ 위험
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.02
✓ 위험
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$12.00
현재가 대비 +383.9%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+17.0%
평균
My positionMid-range
Low range Average High range
미분류 초소형주 Median 25.4% · Bottom 45%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Returns by period
Current position within 52-week range
Low (-49.4%p) High (-97.5%p)
Current price is 49.4% above the 52-week low and 97.5% below the 52-week high
Recent risk (last 65 trading days)
Max drawdown
-95.5%
Annualized volatility
528.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 65-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $2.48 below the midline ($2.61). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 0.084 > Signal 0.082 in positive zone + Hist positive (+0.002). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 49.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 15.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Valuation data is insufficient

Key metrics such as PER and PBR are unavailable, so valuation is omitted.

Who owns it?

Ownership flow is positive
Short interest light 2.5%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
0.0%
Institutions little change
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 0.0%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 45.4%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 54.6%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
2.5%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 45 days Little change
Short interest days to cover
0.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 1.8M주
Float (tradable shares) 1.0M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 45 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
LABT LABT This Stock
$4.3M- - - - -6.1%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 레이크우드-아메덱스 바이오테라퓨틱스(LABT)?

레이크우드-아메덱스 바이오테라퓨틱스(LABT) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of LABT?

The market cap of LABT is approximately $4M, ranking 5,701 within its sector.

What is the 52-week high and low for LABT?

LABT has recorded a 52-week high of $98.20 and a low of $1.66.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.